NASDAQ:ATRA
Atara Biotherapeutics Stock News
$0.700
+0.0390 (+5.90%)
At Close: Mar 27, 2024
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
04:01pm, Wednesday, 06'th Jul 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
02:31pm, Monday, 23'rd May 2022
Late last week, Atara Biotherapeutics Inc (NASDAQ: ATRA) announced that Bayer AG (OTC: BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted all
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Thursday, 05'th May 2022
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for
04:33pm, Tuesday, 26'th Apr 2022
Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now?
05:00pm, Saturday, 12'th Mar 2022 Stocks Register
Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 03/11/22, with the stock price down by -2.59% to the previous day’s close as strong demand from buyers drove the stock to $9.02. Actively observing the price movement in the last trading, the stock closed the session at $9.26, falling within a range of $9.00 … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now? Read More »
Atara Biotherapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
06:16am, Tuesday, 01'st Mar 2022 Seeking AlphaAtara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
03:49am, Tuesday, 01'st Mar 2022 Seeking AlphaAtara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
10:49pm, Monday, 28'th Feb 2022
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
Atara Biotherapeutics GAAP EPS of -$0.96 misses by $0.37, revenue of $7.55M misses by $27.59M
09:12pm, Monday, 28'th Feb 2022 Seeking Alpha
Atara Biotherapeutics press release (NASDAQ:ATRA): Q4 GAAP EPS of -$0.96 misses by $0.37.Revenue of $7.55M misses by $27.59M.
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
09:05pm, Monday, 28'th Feb 2022 Investors Atara Bio
Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
07:08pm, Monday, 28'th Feb 2022
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics Q4 2021 Earnings Preview
10:35pm, Sunday, 27'th Feb 2022 Seeking Alpha
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.69 (+27.4% Y/Y) and…
Atara Biotherapeutics: Early Stage Promises, Late Stage Delays
10:21am, Sunday, 27'th Feb 2022 Seeking AlphaIs a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?
03:25pm, Thursday, 24'th Feb 2022
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Atara Biotherapeutics Stock Is Sinking Today
03:47pm, Friday, 18'th Feb 2022 The Motley Fool
A fatality in an early-stage clinical trial is weighing on the cell therapy company''s stock today.